DBL Octreotide Injection (octreotide) 0.05 mg/1mL injection solution vial Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

dbl octreotide injection (octreotide) 0.05 mg/1ml injection solution vial

pfizer australia pty ltd - octreotide, quantity: 0.05 mg - injection, solution - excipient ingredients: sodium acetate trihydrate; water for injections; glacial acetic acid; sodium chloride

DBL Octreotide Injection (octreotide) 0.5 mg/1mL injection solution vial Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

dbl octreotide injection (octreotide) 0.5 mg/1ml injection solution vial

pfizer australia pty ltd - octreotide, quantity: 0.5 mg - injection, solution - excipient ingredients: glacial acetic acid; sodium acetate trihydrate; sodium chloride; water for injections

DBL Octreotide Injection (octreotide) 0.1 mg/1mL injection solution vial Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

dbl octreotide injection (octreotide) 0.1 mg/1ml injection solution vial

pfizer australia pty ltd - octreotide, quantity: 0.1 mg - injection, solution - excipient ingredients: water for injections; sodium acetate trihydrate; glacial acetic acid; sodium chloride

OCTREOTIDE ACETATE injection, solution Združene države Amerike - angleščina - NLM (National Library of Medicine)

octreotide acetate injection, solution

sagent pharmaceuticals - octreotide acetate (unii: 75r0u2568i) (octreotide - unii:rwm8ccw8gp) - octreotide acetate injection is indicated to reduce blood levels of growth hormone (gh) and insulin growth factor-1 (igf-1; somatomedin c) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. the goal is to achieve normalization of gh and igf-1 (somatomedin c) levels (see dosage and administration ). in patients with acromegaly, octreotide acetate injection reduces gh to within normal ranges in 50% of patients and reduces igf-1 (somatomedin c) to within normal ranges in 50% to 60% of patients. since the effects of pituitary irradiation may not become maximal for several years, adjunctive therapy with octreotide acetate injection to reduce blood levels of gh and igf-1 (somatomedin c) offers potential benefit before the effects of irradiation are manifested. improvement in clinical signs and symptoms, or reduction in tumor size or rate of growth, were not shown in clinical trials p

Octreotide 50 micrograms/ml solution for injection Malta - angleščina - Medicines Authority

octreotide 50 micrograms/ml solution for injection

fresenius kabi limited cestrian court, eastgate way, manor park, runcorn, cheshire wa7 1nt, united kingdom - octreotide - solution for injection - octreotide 50 µg/ml - pituitary and hypothalamic hormones and analogues

Octreotide 100 micrograms/ml solution for injection Malta - angleščina - Medicines Authority

octreotide 100 micrograms/ml solution for injection

fresenius kabi limited cestrian court, eastgate way, manor park, runcorn, cheshire wa7 1nt, united kingdom - octreotide - solution for injection - octreotide 100 µg/ml - pituitary and hypothalamic hormones and analogues

Octreotide 500 micrograms/ml solution for injection Malta - angleščina - Medicines Authority

octreotide 500 micrograms/ml solution for injection

fresenius kabi limited cestrian court, eastgate way, manor park, runcorn, cheshire wa7 1nt, united kingdom - octreotide - solution for injection - octreotide 500 µg/ml - pituitary and hypothalamic hormones and analogues